NIH awards $15 million to support development of 3-D human tissue models

More than 60 percent of investigational drugs fail in human clinical trials due to a lack of effectiveness, despite promising pre-clinical studies using cell and animal research models. To help combat this translational science problem, the National Institutes of Health announced 13 two-year awards totaling about $15 million per year, with FY18 funds subject to availability, to develop 3-D microphysiological system platforms that model human disease. The funding is for the first phase of a five-year program. These platforms, called "tissue chips," support living cells and human tissues to mimic the complex biological functions of human organs and systems and provide a new way to test potential drug efficacy.

These Tissue Chip for Disease Modeling and Efficacy Testing awards may enable scientists to better understand disease mechanisms and predict more accurately how patients will respond to specific drugs. The support is made possible through NIH's National Center for Advancing Translational Sciences' (NCATS) Tissue Chip for Drug Screening program, which leads this effort in collaboration with other NIH Institutes and Centers.

"The goal is for these tissue chips to provide more accurate platforms to understand diseases, and to be more predictive of the human response to drugs than current research models, thereby improving the success rate of candidate drugs in human clinical trials," said NCATS Director Christopher P. Austin, M.D.

NCATS launched its Tissue Chip program in 2012 to lead the development of highly innovative microphysiological systems to study drug safety and toxicity in a faster, more effective way than current methods. The tissue chips can be integrated to form a human body-on-a-chip, enabling researchers to study investigational drugs and therapeutic agents across the entire body prior to human clinical trials. The new Tissue Chip awardees will study a wide range of common and rare diseases, from rheumatoid arthritis, kidney disease and human influenza A viral infection to amyotrophic lateral sclerosis (ALS), hereditary hemorrhagic telangiectasia and arrhythmogenic cardiomyopathy.

In the second phase of the awards, researchers will partner with pharmaceutical companies to further evaluate the usefulness of validated disease models - those that accurately mimic disease biology - in assessing the effectiveness of candidate drugs.

In addition to NCATS, NIH Institutes and Centers funding the new awards include the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute for Diabetes and Digestive and Kidney Diseases, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, National Heart, Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the NIH Office of Research on Women's Health.

The 2017 awardees are:

Brigham and Women's Hospital, BostonJoseph Vincent Bonventre, M.D., Ph.D., and Luke Lee, Ph.D. (University of California, Berkeley)Kidney Microphysiological Analysis Platforms to Optimize Function and Model DiseaseGrant Number: 1-UG3-TR-002155-01

Cedars-Sinai Medical Center, Los AngelesClive Niels Svendsen, Ph.D. Development of a Microphysiological Organ-on-Chip System to Model ALS and Parkinson's DiseaseGrant Number: 1-UG3-NS-105703-01

Columbia University, New York CityGordana Vunjak-Novakovic, Ph.D. Multi-Tissue Platform for Modeling Systemic PathologiesGrant Number: 1-UG3-EB-025765-01

Duke University, Durham, N.C.George A. Truskey, Ph.D.Systemic Inflammation in Microphysiological Models of Muscle and Vascular DiseaseGrant Number: 1-UG3-TR-002142-01

Harvard University, Cambridge, Mass.Donald E. Ingber, M.D., Ph.D. Lung-on-a-Chip Disease Models for Efficacy TestingGrant Number: 1-UG3-HL-141797-01

Harvard University, Cambridge, Mass.Kevin Kit Parker, Ph.D., and William Tswenching Pu, M.D. Multi-Scale Modeling of Inherited Pediatric CardiomyopathiesGrant Number: 1-UG3-HL-141798-01

Northwestern University, Evanston, Ill. Teresa K. Woodruff, Ph.D. Polycystic Ovary Syndrome and Androgen-Related Disease Modeling and Drug Testing in Multi-Organ Integrated Microfluidic Reproductive PlatformGrant Number: 1-UG3-ES-029073-01

University of California, DavisSteven Carl George, M.D., Ph.D., David Terry Curiel, M.D., Ph.D., (Washington University in St. Louis) and Stacey Lynn Rentschler, M.D., Ph.D. (Washington University in St. Louis)A 3-D In Vitro Disease Model of Atrial ConductionGrant Number: 1-UG3-HL-141800-01

University of California, IrvineChristopher C.W. Hughes, Ph.D. Microphysiological Systems to Model Vascular MalformationsGrant Number: 1-UG3-HL-141799-01

University of Pittsburgh, Pittsburgh, Pa.Rocky S. Tuan, Ph.D. Tissue Chip Modeling of Synovial Joint Pathologies: Effects of Inflammation and Adipose-Mediated Diabetic ComplicationsGrant Number: 1-UG3-TR-002136-01

University of Rochester, Rochester, N.Y.Danielle S. Benoit, Ph.D., Lisa A. Delouise, Ph.D., and Catherine Ovitt, Ph.D.Engineered Salivary Gland Tissue ChipsGrant Number: 1-UG3-DE-027695-01

University of Washington, SeattleJonathan Himmelfarb, M.D.A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingGrant Number: 1-UG3-TR-002158-01

Vanderbilt University, Nashville, Tenn. Aaron B. Bowman, Ph.D., Kevin C. Ess, M.D., Ph.D., and John Peter Wikswo, Ph.D.Drug Development for Tuberous Sclerosis Complex and Other Pediatric Epileptogenic Diseases Using Neurovascular and Cardiac Microphysiological ModelsGrant Number: 1-UG3-TR-002097-01

Provided by National Institutes of Health